Translational Research Evaluating Neurocognitive Memory Processes

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01834677

Acronym

TREC-MP

Enrollment

Registered

2013-04-18

Start date

2013-04-30

Completion date

2015-11-30

Last updated

2015-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurocognition

Keywords

Depression, Neurocognition, Electroconvulsive Therapy (ECT), Parkinson's Disease

Brief summary

The purpose of this study is to evaluate the psychometric properties and utility of new, computerized, neurocognitive measures in humans with depression, and humans with depression undergoing electroconvulsive therapy (ECT). The benefits of the study outweigh the risk as there is the possibility of developing better computerized neurocognitive measures, and the risks are limited to no more than minimal test related fatigue and psychological stress. Depressed humans, depressed human participants undergoing ECT, and humans diagnosed with Parkinson's disease (age 18-85) will be invited to participate in this study. After providing informed consent participants will undergo a clinical psychiatric evaluation to confirm the inclusion/exclusion criteria. After the clinical psychiatric evaluation, participants will complete common and new neurocognitive measures. There will be a total of two testing visits (baseline, 1-month follow-up). The anticipated duration of the participant's involvement is no more than 2 study visits that can take place over a 4-day period (i.e., the clinical evaluation can occur on day 1 and the neuropsychological measures can be administered on day 2 of each study visit) equating to approximately 6-hours (3-hours each day) per study visit.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

Depressed Individuals 1. Male and female subjects, age 18-85 2. DSM-IV-TR diagnosis of major depressive episode, unipolar, confirmed by the MINI-PLUS \[221\] 3. HRSD24 total score \> 10 4. MMSE total score \> 26 5. Graduated from high school 6. Competent to provide informed consent Inclusion Criteria:Depressed Individuals Receiving ECT 1. Same as for Depressed Cohort Inclusion Criteria (see above) 2. Referred for ECT 3. Subject competent to provide informed consent Inclusion Criteria:Individuals Diagnosed with PD 1. Male and female subjects, age 18-85 2. Diagnosed with PD 3. MMSE total score \> 20 4. Graduate high school 5. Subject competent to provide informed consent

Exclusion criteria

Depressed Individuals/Depressed Individuals Receiving ECT 1. Lifetime history of bipolar disorder, schizophrenia, schizoaffective disorder, or mental retardation 2. Current neurostimulation treatment (e.g., ECT, MST, rTMS, vagus nerve stimulation, deep brain stimulation) 3. Current alcohol abuse or dependence within past 12 months 4. Current substance abuse or dependence within past 12 months 5. Lifetime mental retardation 6. History of central nervous system (CNS) disease 7. Current diagnosis of dementia or delirium 8. Current visual, auditory, or motor impairment that compromises ability to take tests 9. Unable to read or comprehend English

Design outcomes

Primary

Measure	Time frame	Description
California Verbal Learning Test-II	Baseline	The California Verbal Learning Test-II (CVLT-II) is a standard neuropsychological instrument that assesses verbal learning and memory.

Countries

United States

Outcome results